Assistant Professor Shruti BHATT

Department of Pharmacy, National University of Singapore
18 Science Drive 4, Singapore 117543

Office: Blk S7 Level 2 (Room 16), Science Drive 3
Lab: Blk S7 Level 2 (Room 05), Science Drive 3
Tel: +65 65168014

2014 Ph.D. in Molecular and Cellular Pharmacology
University of Miami, Florida, United States
2008 M.S. in Pharmacology and Toxicology
Long Island University (LIU), New York, United States
2005 B.S. in Pharmacy
Maharaja Sayajirao University (MSU), Gujarat, India
2020 – present Assistant Professor
Department of Pharmacy
National University of Singapore, Singapore
2020 – present Principle Associate
Cancer Science Institute Singapore, Singapore
2020 – present Visiting Scientist
Dana-Farber Cancer Institute, Boston, United States
2014 –2020 Research fellow
Medical Oncology, Dana-Farber Cancer Institute, Harvard
Medical School, Boston, United States
Jan 2013 US Patent Application # US 14/373/137
Compositions, Methods and Kits for Treatment of Cancer and Autoimmune Diseases.
2020 NUS Resilience and Growth Initiative Award
2019 William Guy Forbeck Scholar Award
2018 Claudia-Adams Barr Award
2017 AACR Scholar-in-Training Award
2017 ASH-EHA Translational Research Training in Hematology Award
2016 AACR Basic Cancer Research Fellowship Award
2016 LLS Career Development Award for FELLOW

Research focus of my laboratory is to identify treatment strategies and underlying mechanism of therapy-resistant cancers by studying phenotypic and genotypic tumor characteristics. I am most intrigued by the heterogeneous response of cancers to a wide range of therapies. By using mitochondrial priming as a platform, we have found that early changes in mitochondrial signaling can assign individualized in-vivo therapy for acute myeloid leukemia PDX models and patient tumors.
The primary goals of my laboratory are (i) to measure mitochondrial apoptosis signaling using BH3 profiling to accurately predict response to targeted therapy in blood cancer (ii) to understand why some leukemia cells persist during therapy (iii) to determine how to combine functional and genomic approaches to guide precision target identification in a relapsed cancers (iv) to study clonal architecture of leukemia relapse. To investigate these problems, we are doing functional measurements to determine how chemical vulnerabilities evolve during leukemia treatment and whether drug sensitivities in a relapsed disease can be linked to genetic abnormalities. We are performing multi-dimensional studies involving mitochondrial outer membrane potential measurements, targeted exome sequencing, transcriptomics and DNA barcoding. We are exploiting human blood cancer cell lines, patient-derived xenograft models and primary tumor specimens to address our hypothesis.

NCBI Pubmed link:

    • Garcia JS*, Bhatt S*, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A
      Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 Mar;95(3):245-250.
    • Sperling A, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Slabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Mariateresa, Fulciniti M, Namrata D. Udeshi ND3, Kuhn E, Letai A, Munshi N, Carr SA, and Ebert BL.
      Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs. Blood 2019 July 11; 134(2):160-170.
    • Kahn JD, Miller P, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Zhu H, Mar B, Mertins P, Fereshetian S, Krug K, Letai A, Carr SA, Doench J, Jaiswal S*, Ebert BL*.
      PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibitor in hematopoietic cells. Blood 2018 Sept 13; 132(11): 1095-1105.
    • Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.
      Statins Enhance Efficacy of Venetoclax in Blood Cancers. Sci Trans Med. 2018 Jun 13; 10(445).
    • Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS.
      Anti-CD20-Interleukin-21 Fusokine Targets Malignant B-cells via Direct Apoptosis and NK-cell Dependent Cytotoxicity. Blood. 2017 Apr 20; 129(16):2246-2256.
    • Bhatt S, Sarosiek KA, Lossos IS.
      Interleukin-21: Its Potential Role in the Therapy of Lymphoma. Leuk Lymphoma. 2017 Jan; 58(1): 17-29.
    • Bhatt S, Matthews J, Parvin S, Sarosiek K, Zhao D, Jiang X, Letai A, Lossos I.
      Direct & Immune Mediated Cytotoxicity of Interleukin-21 Contributes to Anti-tumor Effects in Mantle Cell Lymphoma. Blood 2015;126(13):1555-64.
    • Zhu D*, Bhatt S*, Lu X, Guo F, Veelken H, Hsu DK, Liu F, Cubela SA, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos I.
      Chlamydophila Psittaci Negative Ocular Adnexal Marginal Zone Lymphomas Express Self Polyreactive B cell Receptors. Leukemia. 2015 29(7); 1578-99.
    • Bhatt S, Ashlock B, Natkunam Y, Sujoy V, Chapman J, Ramos J, Mesri E, Lossos I. CD30 Targeting with Brentuximab Vedotin- a Novel Therapeutic Approach to Primary Effusion Lymphoma. Blood. 2013;122(7):1233-42.
    • Bhatt S*, Ashlock BM*, Toomey NL, Diaz, Mesri, Lossos I, Ramos JC.
      Efficacious Lytic-induction Therapy for Primary Effusion Lymphoma without KSHV Production, J of Clin Invest. 2013;123(6):2616-28.